269 related articles for article (PubMed ID: 16204076)
1. Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function.
Escuin D; Kline ER; Giannakakou P
Cancer Res; 2005 Oct; 65(19):9021-8. PubMed ID: 16204076
[TBL] [Abstract][Full Text] [Related]
2. Microtubules regulate hypoxia-inducible factor-1α protein trafficking and activity: implications for taxane therapy.
Carbonaro M; Escuin D; O'Brate A; Thadani-Mulero M; Giannakakou P
J Biol Chem; 2012 Apr; 287(15):11859-69. PubMed ID: 22367210
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of natural product microtubule stabilizers on microtubule assembly: single agent and combination studies with taxol, epothilone B, and discodermolide.
Gertsch J; Meier S; Müller M; Altmann KH
Chembiochem; 2009 Jan; 10(1):166-75. PubMed ID: 19058273
[TBL] [Abstract][Full Text] [Related]
4. A quantitative evaluation of the effects of inhibitors of tubulin assembly on polymerization induced by discodermolide, epothilone B, and paclitaxel.
Dabydeen DA; Florence GJ; Paterson I; Hamel E
Cancer Chemother Pharmacol; 2004 May; 53(5):397-403. PubMed ID: 15060743
[TBL] [Abstract][Full Text] [Related]
5. Suppression of microtubule dynamics by discodermolide by a novel mechanism is associated with mitotic arrest and inhibition of tumor cell proliferation.
Honore S; Kamath K; Braguer D; Wilson L; Briand C; Jordan MA
Mol Cancer Ther; 2003 Dec; 2(12):1303-11. PubMed ID: 14707271
[TBL] [Abstract][Full Text] [Related]
6. Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs.
Chen JG; Horwitz SB
Cancer Res; 2002 Apr; 62(7):1935-8. PubMed ID: 11929805
[TBL] [Abstract][Full Text] [Related]
7. Microtubule disruption utilizes an NFkappa B-dependent pathway to stabilize HIF-1alpha protein.
Jung YJ; Isaacs JS; Lee S; Trepel J; Neckers L
J Biol Chem; 2003 Feb; 278(9):7445-52. PubMed ID: 12488445
[TBL] [Abstract][Full Text] [Related]
8. Insights into the interaction of discodermolide and docetaxel with tubulin. Mapping the binding sites of microtubule-stabilizing agents by using an integrated NMR and computational approach.
Canales A; Rodríguez-Salarichs J; Trigili C; Nieto L; Coderch C; Andreu JM; Paterson I; Jiménez-Barbero J; Díaz JF
ACS Chem Biol; 2011 Aug; 6(8):789-99. PubMed ID: 21539341
[TBL] [Abstract][Full Text] [Related]
9. EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1.
Thomas SL; Zhong D; Zhou W; Malik S; Liotta D; Snyder JP; Hamel E; Giannakakou P
Cell Cycle; 2008 Aug; 7(15):2409-17. PubMed ID: 18682687
[TBL] [Abstract][Full Text] [Related]
10. Strategies for the development of novel Taxol-like agents.
Mooberry SL
Methods Mol Med; 2007; 137():289-302. PubMed ID: 18085237
[TBL] [Abstract][Full Text] [Related]
11. Epothilone B enhances surface EpCAM expression in ovarian cancer Hey cells.
Shahabi S; Yang CP; Goldberg GL; Horwitz SB
Gynecol Oncol; 2010 Nov; 119(2):345-50. PubMed ID: 20674962
[TBL] [Abstract][Full Text] [Related]
12. Late activation of apoptotic pathways plays a negligible role in mediating the cytotoxic effects of discodermolide and epothilone B in non-small cell lung cancer cells.
Bröker LE; Huisman C; Ferreira CG; Rodriguez JA; Kruyt FA; Giaccone G
Cancer Res; 2002 Jul; 62(14):4081-8. PubMed ID: 12124345
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
[TBL] [Abstract][Full Text] [Related]
14. M410, a combretastatin A4 analogue, disrupts microtubules and inhibits HIF-1α in human breast cancer cells.
Yang H; Xia Q; Zou Y; Wang K; Jiang W; Cai Y
Oncol Rep; 2015 Jul; 34(1):334-40. PubMed ID: 25976207
[TBL] [Abstract][Full Text] [Related]
15. Microtubule stabilizing agents: their molecular signaling consequences and the potential for enhancement by drug combination.
Bergstralh DT; Ting JP
Cancer Treat Rev; 2006 May; 32(3):166-79. PubMed ID: 16527420
[TBL] [Abstract][Full Text] [Related]
16. Role of vincristine in the inhibition of angiogenesis in glioblastoma.
Park KJ; Yu MO; Park DH; Park JY; Chung YG; Kang SH
Neurol Res; 2016 Oct; 38(10):871-9. PubMed ID: 27472259
[TBL] [Abstract][Full Text] [Related]
17. Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines.
Martello LA; McDaid HM; Regl DL; Yang CP; Meng D; Pettus TR; Kaufman MD; Arimoto H; Danishefsky SJ; Smith AB; Horwitz SB
Clin Cancer Res; 2000 May; 6(5):1978-87. PubMed ID: 10815923
[TBL] [Abstract][Full Text] [Related]
18. Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest.
Kamath K; Jordan MA
Cancer Res; 2003 Sep; 63(18):6026-31. PubMed ID: 14522931
[TBL] [Abstract][Full Text] [Related]
19. Microtubular stability affects cardiomyocyte glycolysis by HIF-1alpha expression and endonuclear aggregation during early stages of hypoxia.
Teng M; Dang YM; Zhang JP; Zhang Q; Fang YD; Ren J; Huang YS
Am J Physiol Heart Circ Physiol; 2010 Jun; 298(6):H1919-31. PubMed ID: 20228255
[TBL] [Abstract][Full Text] [Related]
20. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells.
Giannakakou P; Gussio R; Nogales E; Downing KH; Zaharevitz D; Bollbuck B; Poy G; Sackett D; Nicolaou KC; Fojo T
Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2904-9. PubMed ID: 10688884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
